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S318 Poster Session IConclusion:Children and adolescents who undergo RTC appear to
have significantly better PF outcomes one to two years after SCT
versus those undergoingMAC. Development of cGVHD is a signif-
icant predictor of PF deterioration.
Table 1. Pulmonary Function Testing Before and After SCT
Pre-SCT Mean Post-SCT Mean
N (%-predicted) (%-predicted) p-valueFVC 40 85.5±2.4% 77.2±2.6% <0.0001
FEV1 40 88.7±3.0% 79.5±2.9% <0.0001
TLC 26 92.7±3.3% 85.0±3.7% 0.012
DLCO 35 72.6±3.3% 66.0±3.3% 0.033
FEV1/FVC 40 102.8±1.6% 103.1±1.5% 0.837302
THE FREQUENCY OF INTERVAL SURVEILLANCE IN THE ADULT HEMATO-
POIETIC STEM CELL TRANSPLANT SURVIVOR
Beavers-Kirby, J.R.1, McDaniel, J.2, Barker, E.2, Lester, J.1,2,
Warren, B.2 1The Ohio State University James Cancer Hospital and So-
love Research Institute, Columbus, OH; 2The Ohio State University, Co-
lumbus, OH
Cancer treatments for hematologic malignancies can include radi-
ation, chemotherapy, immunosuppression, stem cell transplant, and
targeted biological therapies. These therapies can cause long-term
side effects that may negatively affect quality of life. This plan is
most effective when factors such as past treatments, chromosomal
prognostic factors, comorbid health conditions, and lifestyle behav-
iors are considered.
A survivorship care plan specific for cancer survivors who have un-
dergone a hematopoietic stem cell transplant (HSCT) would en-
hance the ability of clinicians to monitor for late effects. The
Center for International Blood and Marrow Transplant Research,
the European Group for Blood and Marrow Transplantation, and
the American Society for Blood and Marrow Transplant have re-
commended that a HSCT-specific survivorship care plan include
6-month, 12-month, and annual assessments of physical and psycho-
social well-being including preventive screenings unique to the
HSCT survivor.
The purpose of this quality improvement study was to describe the
frequency of documentation of the recommended cancer survivor-
ship guidelines by oncology clinicians in the medical records of adult
HSCT survivors at 12 and 24months post-transplant in one compre-
hensive cancer center. This retrospective chart reviewwas conducted
over 2 years. Charts were selected based on length of time since
HSCT. Over 300 charts were included in this study. Only 3 of the
29 recommended guidelines were documented as being completed
in more than 50% of the charts at 12 and 24 months. These 3 indi-
cators included aggressive management of blood pressure, serum
blood urea nitrogen and creatinine and serum liver function testing.
There were 2 additional indicators which were documented as com-
pleted in more than 50% of the charts at 12 months post HSCT, but
less than 50% of the charts at 24 months post HSCT. These indica-
tors were ‘consideration of herpes simplex virus and antifungal pro-
phylaxis’ and ‘pneumocystis carinii pneumonia prophylaxis.’
Additionally, the data indicated that the remaining indicators were
documented in less than 50% of the charts at both 12 and 24months.
These findings were used to inform the oncology clinicians of the
need for adherence to recommended guidelines and in the planning
of a hematology and transplant survivorship clinic for individuals
who have completed the acute phase of their cancer treatment.
Table. Treatment Summary
Diagnosis:
Date of diagnosis Age at diagnosis Date therapy complete
Prognostic features CytogeneticsSummary of treatment:
Treatment Center(s):
Past Medical History
Problem Ongoing Therapy(Continued )Table. (Continued )
Diagnosis:
Date of diagnosis Age at diagnosis Date therapy complete




Date Site TherapySecondary Malignancy
Date Site TherapyProtocol(s)
Acronym/Number Therapy and datesChemotherapy
Date(s) Drug Name/Route Total doseRadiation
Type/Site Date Dose per fraction/Total DoseSurgery
Date Procedure Institute/SurgeonTransfusion History
Transfusion Reaction Pre Medication
Adverse Drug Reactions/Allergies
Drug ReactionHemtopoietic Stem Cell Transplant
Date of Transplant:
Autologous or Allogeneic:












GVHD Treatment SummaryDrug Start Date Stop Date
HSCT Complications/Late EffectsProblem Dates Ongoing Therapy303
A SNAPSHOT OF MY LIFE: PHOTOVOICE PHOTOGRAPHY PROJECT
Schmid, C.L.1, Donnelly, M.M.1, Davies, S.M.1, Vaughn, L.M.2 1Cin-
cinnati Children’s Hospital Medical Center, Cincinnati, OH; 2Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
The Bone Marrow Transplant Unit in the Cancer and Blood Dis-
eases Institute is a place of hope for many patients and families im-
pacted with diseases ranging from cancer, bone marrow failure to
immunology disorders. When most other treatments have failed,
and bone marrow transplant is a viable option, the families will typ-
ically proceed with this treatment. What follows is a prolonged hos-
pitalization with an even greater length of follow-up. The need to
address the patients’ and families’ psychological well-being and cop-
ing strategies becomes a priority during such an extended inpatient
stay, and finding creative ways to do so can be challenging. Through
this concern, A Snapshot of My Life: Photovoice Photography Project was
developed to support patients in processing and sharing their feel-
ings and experiences. Patients, ages five to 23 were loaned digital
cameras to record days in their lives on the BMT unit. During the
review of photos, social workers interacted with the patient to elicit
feelings connected to the photos, creating a therapeutic environment
for the patient and family. This presentation will discuss the Photo-
voice demonstration project on a pediatric bone marrow transplant
unit from inception to implementation. The impact on the patient,
relationship between patient and caregiver, and the influence of
the project on the medical team and therapeutic relationships will
be shared. As a result of the project, a deeper understanding of the
emotional impact a bone marrow transplant and subsequent treat-
ment has on patients was gained. In addition, the therapeutic
Poster Session I S319relationship between social worker and patient was positively im-
pacted and the medical team gained insight into the psychological
impact of treatment. Qualitative findings have been obtained during
the initial demonstration project: IRB approval pending for follow-
up study in 2011/2012.
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VORICONAZOLE THERAPEUTIC MONITORING IN A LEUKEMIA AND BONE
MARROW TRANSPLANT CENTER
Leech, M.1, LaPorte, J.1, Mihelic, R.1, Sanacore, M.1, Sizemore, C.1,
Zhang, X.2, Penland, P.1, Holland, H.K.2, Morris, L.E.2, Bashey, A.2,
Solomon, S.R.2 1The Blood and Marrow Transplant Program, Northside
Hospital, Atlanta, GA; 2The Blood and Marrow Transplant Group of
Georgia, Atlanta, GA
Objectives: The FDA recommends voriconazole (VOR) levels
$0.5mg/L, however current literature recommends trough concen-
trations of $1-2mg/L and \5.5mg/L. We implemented a VOR
therapeutic monitoring program based on our current algorithm
which strives for a level of $0.5 for prophylaxis and $2 for em-
piric/treatment therapy. Our primary objective was to determine
the likelihood of achieving therapeutic levels, and if dose modifica-
tion can be helpful in optimizing attainment of therapeutic levels.
Methods: We prospectively studied steady state VOR levels in 89
consecutive patients (pts) between 02/2010 and 07/2011. Pts in the
prophylaxis group received 200mg BID. Pts in the empiric group re-
ceived 6mg/kg BID for two doses, followed by 4mg/kg BID. Fifty of
the pts had undergone allogeneic HSCT (56%), 38 were undergoing
leukemia therapy (43%), and 1 was an autologous transplant pt.
GVHD was documented in 20/50 HSCT pts (40%), and 5 of those
had gut GVHD.
Results: VOR was being used as prophylaxis in 49/89 pts (55%). A
target level of $0.5 mg/L was achieved in 86% (42/49) of pts. The
level was $1, $2, and $5.5 mg/L in 61%, 43%, and 0%, respec-
tively. Of the 7 pts not reaching $0.5, five doses were increased
with subsequent level $0.5 mg/L. VOR was being used for empiric
therapy in 40/89 pts (45%). Levels achieved target of$2 mg/L in 30
(75%) of 40 pts. Levels were$0.5,$1, and$5.5mg/L in 85%, 82%,
and 40%, respectively. Of the 10 pts with levels\2 mg/L, VOR was
discontinued in 3 pts and dose was increased in 6 pts. Of the 6 in-
creased doses, 3 follow-up levels were obtained and 2 were $2.
The dose of VOR was decreased in 9 pts with level $5.5. Patients
receiving prophylactic VOR were statistically more likely to achieve
targeted levels ($0.5) than pts receiving empiric VOR ($2) (96% vs
80%, p 5 0.038). The presence of gut GVHD was associated with
a statistically significant decrease in achievement of therapeutic
VOR levels compared with GVHD pts without gut involvement
(60% vs 100%, p 5 0.034). However, all GVHD pts achieved ther-
apeutic levels after dose modification.
Conclusion: Utilizing a prospective VOR monitoring program, we
were able to demonstrate that the majority of unselected leukemia
and HSCT pts achieve therapeutic VOR levels. VOR level monitor-
ing allowed for documentation of compliance, gave opportunity for
dose modification to ensure achievement of therapeutic levels, and
reduced toxicity by identifying super-therapeutic levels.305
MUC1 INHIBITION REVERSES THE POOR IMMUNOGENICITY OF LEUKE-
MIA STEM CELLS RENDERING THEM SUSCEPTIBLE TO IMMUNOTHERAPY
Rosenblatt, J.1, Stroopinsky, D.1, Mills, H.1, Luptakova, K.1, Vasir, B.2,
Joyce, R.M.1, Levine, J.D.1, Tzachanis, D.1, Arnason, J.1, Galinsky, I.2,
Stone, R.2, Kufe, D.2, Reiter, Y.3, Avigan, D.E.1 1Beth Israel Deaconess
Medical Center, Boston, MA; 2Dana-Farber Cancer Institute, Boston,
MA; 3Technion-Israel Institute of Technology, Haifa, Israel
Acute myeloid leukemia (AML) arises from a leukemia stem cell
(LSC) population that is resistant to cytotoxic therapy and serves
as a reservoir for relapse. We have demonstrated that the MUC1 tu-
mor antigen is selectively expressed by LSCs but not normal hema-
topoietic stem cells. We subsequently assessed whether LSCs
effectively present MUC1 antigen providing a therapeutic target
for cellular immunotherapy. To investigate this issue we utilized
a novel class of human T Cell Receptor-Like Antibodies (TCRL)which target MUC1 peptide-HLA-A2.1 complex and can be used
to quantify the density of antigen presentation by LSCs.CD34+ cells
were isolated from HLA-A2.1 AML patients and were analyzed for
expression of MUC1 protein with the DF3 anti-MUC1 antibody
and for HLA presentation of MUC1 peptide with the HLA-A2.1/
MUC1 TCRL. Remarkably, despite the strong surface expression
of the MUC1 protein (mean expression 68%, n 5 8), low levels of
HLA bound MUC1 peptide was detected (mean expression 7.6%,
n 5 8). Similarly, leukemia progenitors minimally express HLA-
A2-WT1 peptide complexes (mean expression 5%, n 5 3). These
findings suggest that leukemia progenitors exhibit an immuno-priv-
ileged phenotype, potentially shielding them from immunotherapy.
We have developed aMUC1 inhibitor peptide, G0-203, that induces
differentiation and apoptosis of leukemia progenitors. We evaluated
whether, in addition to inducing differentiation of leukemia progen-
itors, exposure to GO-203 would augment antigen presentation. Ex-
posure of CD34+ AML cells to 5mM GO-203 for 24 hours
upregulated the mean expression of HLA-A2.1/MUC1 peptide
complexes (10% to 62%; n 5 4, p 5 0.001). Consistent with these
findings, GO-203-treated leukemia progenitors exhibited an in-
crease in potency as antigen presenting cells, as manifested by their
stimulation of autologous T cells and expansion of antigen specific
T cells. In addition, GO-203 exposure increased susceptibility of
leukemia progenitors to targeting by T cells stimulated by an autol-
ogousDC/AML fusion vaccine, as manifested by a 3 -fold increase in
Granzyme B activity. In conclusion, the results demonstrate that
leukemia progenitors exhibit low levels of antigens presentation, re-
sulting in their poor immunogenicity and potential resistance to im-
munotherapy. Exposure of leukemia progenitors to a MUC1
inhibitor peptide, GO-203, upregulates HLA presentation of leuke-
mia associated antigens, rendering these cells more susceptible to
immune targeting.
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USE OF THE VETERANS AFFAIRS NUTRITIONAL STATUS CLASSIFICATION
SCHEME IN THE EVALUATION OF SURVIVAL AFTER AUTOLOGOUS PE-
RIPHERAL BLOOD STEM CELL TRANSPLANTATION
Toro, J.J.1,2, Haile, D.J.1, Lee, S.1, Jewell, P.S.1, Freytes, C.O.1,2 1South
Texas Veterans Health Care System, Audie L. Murphy Memorial Vet-
erans Hospital, San Antonio, TX; 2University of Texas Health Science
Center at San Antonio, San Antonio, TX
Background:We have previously reported that the Veterans Affairs
Nutritional Status Classification Scheme (VA-NSCS) can identify
patients (pts) at a higher risk of acute toxicities after autologous pe-
ripheral blood stem cell transplantation (APBSCT) but no studies
have been performed to analyze the impact of the VA-NSCS on sur-
vival [Toro et al, Biol BloodMarrow Transplant 2009;15:1060]. We
analyzed the correlation between the VA-NSCS and survival rates
after APBSCT.
Methods: A total of 231 consecutive pts who underwent APBSCT
for hematologic malignancies at the Audie L. Murphy Memorial
VeteransHospital, between June 2005 andDecember 2010, were an-
alyzed. A registered dietician assessed the nutritional status (NS) of
the pts utilizing the VA-NSCS prior to the administration of the
conditioning regimen. Pretransplant patient characteristics and
posttransplant data on toxicities were obtained from the transplant
program database.
Results: The median age of the study subjects was 60 years (range
19-78). Of the 231 pts, 221 (96%) were males and 127 (55%) were
Caucasian. One hundred sixty-six (72%) pts had multiple myeloma
and received melphalan as conditioning regimen. Sixty-five (28%)
pts had lymphoma and received either BEAM or CVB as condition-
ing regimen. Eighty-two (35%) of the pts had a normal NS, 137
(59%) had mildly compromised NS and 12 (5%) had moderately
compromised NS. No statistically significant differences between
the 3 nutritional status groups were observed with respect to age,
ethnicity or diagnosis. The overall survival (OS) rate at 1 year was
97%with non-relapsemortality of 1%.TheOS rates among normal,
mildly andmoderately compromisedNSwere 78% (64 pts), 68% (93
pts), and 42% (5 pts) respectively (P 5 0.011). The pts with normal
NS were 5.0 times as likely to live as pts with moderately compro-
mised NS (95% CI 5 1.41 to 17.57; P 5 0.009). Consistent with
our previous report, the pts with moderately compromised NS expe-
rienced a significant longer length of hospital stay (36.26 31.5 days)
